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21 Lead (Pb) is a widespread heavy metal which is harmful to human health, especially to young 
22 children. To provide a human health risk assessment that is more relevant to real conditions, 
23 Pb bioavailability in soils is increasingly employed in the assessment procedure. Both in vivo 
24 and in vitro measurements for lead bioavailability are available. In vivo models are time- 
25 consuming and expensive, while in vitro models are rapid, economic, reproducible, and reliable 
26 while involving more uncertainties. Uncertainties in various measurements create difficulties 
27 in accurately predicting Pb bioavailability, resulting in the unnecessary remediation of sites. In 
28 this critical review, we utilised available data from in vivo and in vitro studies to identify the 
29 key parameters influencing the in vitro measurements, and presented uncertainties existing in 
30 Pb bioavailability measurements. Soil type, properties and metal content are reported to 
31 influence lead bioavailability; however, the differences in methods for assessing bioavailability 
32 and the differences in Pb source limit one’s ability to conduct statistical analyses on influences 
33 of soil factors on Pb bioavailability. The information provided in the review is fundamentally 
34 useful for the measurement of bioavailability and risk assessment practices.
35
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68 CEC---------------------------------------------------------------------------cation exchange capacity
69 G-phase-------------------------------------------------------------------------------------gastric phase
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87 Exposure to lead (Pb) is of increasing concern due to the global scale of its occurrence in the 
88 environment and adverse health effects (U.S. Environmental Protection Agency, 2014). Oral 
89 ingestion of Pb contaminated soil is a major pathway for exposure to humans especially 
90 children (U.S. Environmental Protection Agency, 2014). Ingestion of Pb contaminated soils by 
91 children is of particular concern due to their hand-to-mouth activities and higher metabolic rate 
92 (Gulson et al., 1995; Oomen et al., 2003; U.S. Environmental Protection Agency, 2007a), 
93 which will result in a permanent influence on children’s development of neuronal systems, cell 
94 function and a decrease of children’s intelligence quotient (Shannon, 1998). Even at a low 
95 blood lead level, a range of neurocognitive,  behavioural and other specific issues have been 
96 reported as being linked to Pb exposure (Benetou-Marantidou et al., 1988; Dietrich et al., 
97 1990). The U.S. Environmental Protection Agency (EPA) indicates that there is no safe 
98 threshold for children exposed to Pb (U.S. Environmental Protection Agency, 1994, 2007a). 
99
100 Total Pb concentration in contaminated soils contributes  to Pb exposure and influences blood 
101 lead level in children; however, an increasing number of investigations have indicated that 
102 using total Pb concentration may overestimate the risks from Pb exposure (C. R. Janssen  et 
103 al., 2000; Oomen et al., 2006; U.S. Environmental Protection Agency, 2007a; Li et al., 2014; 
104 Wijayawardena et al., 2014), since only a fraction of Pb in ingested soil can cause adverse 
105 effects to human health due to the influence from soil properties and sources, Pb distribution 
106 and metabolism of Pb in organisms (Ruby et al., 1996; Oomen et al., 2006). Usage of the 
107 ‘effective’ fraction of total ingested Pb is recommended to assess risks and adverse effects from 
108 Pb exposure to humans especially children (Ruby et al., 1996; Oomen et al., 2006). 
109 Bioavailability (BA), as a linkage parameter between total concentration and the ‘effective’ 
110 fraction for exposure assessment, holds promise for determining a more realistic basis for 
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111 environmental risk assessment and remediation (Belfroid et al., 1996). The term BA in this 
112 study is defined as the fraction of an ingested dose that crosses the gastrointestinal epithelium 
113 and becomes available for distribution to internal target tissues and organs (U.S. Environmental 
114 Protection Agency, 2007b).
115
116 Extensive research efforts have been made for Pb BA measurement; however, it continues as 
117 a challenge due to the existence of a large number of uncertainties, inadequate information, 
118 and lack of reliable predictive models (U.S. Environmental Protection Agency, 2014). 
119 Although the U.S. EPA has established that relative bioavailability (RBA) of Pb in soil is 60% 
120 in the Integrated Exposure Uptake Biokinetic (IEUBK) model, Pb RBA has been reported to 
121 be wide-ranging. For example, Casteel et al. (2006) reported RBA of Pb using a swine model 
122 ranging from 6% to 105%. 
123
124 Numerous research attempts have been made on measuring Pb BA via in vivo models such as 
125 in swine (Sus scrofa), rats (Rattus), mice (Mus), monkeys (Cercopithecidae), rabbits 
126 (Oryctolagus cuniculus); however, limited data and information are available due to time- 
127 consuming and cost-factors as well as ethical issues (Juhasz et al., 2007; U.S. Environmental 
128 Protection Agency, 2007a). Moreover, challenges exists when extrapolating data from in-vivo 
129 studies to human health due to the physiological differences and species diversity between 
130 humans and the experimental animal models (Ruby et al. 1999). A potential alternative 
131 approach to supersede in vivo studies is the use of in vitro tests to measure Pb bioaccessibility 
132 (BAc) (i.e. the fraction that is soluble in the gastrointestinal environment and is available for 
133 absorption), which are economic, rapid, and reproducible, but involves more uncertainties 
134 (FaciesRuby et al., 1999; C. R. Janssen  et al., 2000). At present there are various in vitro 
135 models being developed to determine Pb BAc, such as the Relative Bioavailability Leaching 
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136 Procedure (RBALP), the unified BioAccessibility Research Group Europe (BARGE) method 
137 (UBM), the Solubility Bioaccessibility Research Consortium assay (SBRC), a Physiologically 
138 Based Extraction Test (PBET), the In Vitro Gastrointestinal (IVG) Method and the In Vitro 
139 Digestion Model (RIVM). Although all these models were validated by various in vivo models 
140 and correlations between in vivo and in vitro models (IVIVC) were found (Ruby et al., 1996; 
141 Schroder et al., 2004; Oomen et al., 2006; Drexler and Brattin, 2007; Juhasz et al., 2009; Denys 
142 et al., 2012), there are still many uncertainties due to varied soil properties and parameters of 
143 each method. For example, for the soils from the same source, the IVIVC based on the same 
144 in vivo model (swine) and different in vitro models (IVG and RIVM), the slopes and r2 differ 
145 from each other (Schroder et al., 2004; Oomen et al., 2006).
146
147 Lead in soil can be distributed in a range of discrete mineral phases, include co-precipitated or 
148 sorbed Pb associated with soil minerals, clay and organic matter (OM), and dissolved Pb that 
149 may be complexed with varied organic and inorganic ligands (Mortvedt, 1991). All these 
150 phases are believed to control Pb dissolution properties and hence influence its BAc 
151 (FaciesRuby et al., 1999). Oomen et al. (2006) stated that Pb BA can be affected by the soil 
152 characteristics and Pb speciation. Moreover, soil properties like clay content, pH, OM, and 
153 cation exchange capacity (CEC) are reported to be related to Pb BAc (Buchter et al., 1989; He 
154 and Singh, 1993; Hornburg and Brümmer, 1993; Rieuwerts et al., 2006; Poggio et al., 2009; 
155 Roussel et al., 2010). All this implies that it may therefore be possible to find a correlation 
156 between Pb BA and soil properties.
157
158 In this critical review, a summary of current measurements of Pb RBA/BAc (in vivo and in 
159 vitro models) is included, with an emphasis on the influence of soil type and properties on Pb 
160 RBA/BAc, and uncertainties in measuring Pb RBA/BAc. An overall understanding is shown 
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161 in Figure 1, which illustrated the relationships between different concepts. The interaction of Pb 
162 contaminants with soil particles influence the Pb RBA/Bac which is to be incorporated in the 
163 risk assessment procedure. Detailed information on the measurement approaches, influence of 
164 soil properties and sources are included in the following sections. The information is important 
165 for understanding critical issues related to Pb RBA/BAc, including the mechanisms of soil 
166 properties in controlling Pb RBA/BAc. Indications on human health risk assessment and 
167 development of technologies for remediation of Pb contaminated soils can be also obtained.
168
169 Figure 1 Illustration of concepts in Pb bioavailability research 
170 (RBALP: the Relative Bioavailability Leaching Procedure; UBM: the unified BioAccessibility Research Group 
171 Europe (BARGE) method; SBRC: the Solubility Bioaccessibility Research Consortium assay; PBET: a 
172 Physiologically Based Extraction Test; IVG: the In Vitro Gastrointestinal (IVG) Method; RIVM: the In Vitro 




175 2 Measurement of Pb bioavailability/bioaccessibility
176 2.1 Pb bioavailability
177 2.1.1 Absolute bioavailability 
178 As stated, BA data is essentially related to the amount of Pb in animal/human bloodstream and 
179 tissues (Wragg and Cave, 2003). The Pb BA is a fraction of a dose of Pb which is referred to 
180 as absolute bioavailability (ABA) (U.S. Environmental Protection Agency, 2007b). The 
181 calculation of ABA in blood is based on the area under curve (AUC) (Error! Reference source 
182 not found.), as defined in Equation 1 where Dose IV is the intravenous dose of reference 
183 material (Pb acetate, µg/L), AUCIV is the area under the blood lead concentration curve after 
184 IV dosage (µg*h/L). These factors subscripted ORAL are equivalent values for oral dose of test 
185 soils/dust (R.Naidu, 2003).
186
187 Figure 2 Bioavailability Plasma-concentration
188  (1) 
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189 2.1.2 Relative bioavailability
190 The Pb RBA is defined as the comparative bioavailability of different forms of Pb containing 
191 the substance (e.g., bioavailability of a metal from soil relative to its bioavailability from Pb 
192 acetate solution) (Ruby et al., 1999). In order to measure Pb RBA in a particular test material 
193 compared to Pb in a reference material (Pb acetate), the underlying principle is that equal 
194 absorbed doses of Pb will produce equal increases in Pb concentration in the tissues of exposed 
195 animals or human (U.S. Environmental Protection Agency, 2007c). This means RBA is the 
196 ratio of oral doses that contribute equal increases in the tissue burden of Pb. Lead RBA in soil 
197 has been measured either via blood or via tissues such as kidney, liver, femur and urine (Denys 
198 et al., 2012). The determination of Pb RBA in soil using blood is defined in Equation 2, where 
199 ABAsoil is the absolute bioavailability of soil, Dosesoil is the Pb concentration of oral dose 
200 (µg/L) that is given, AUCsoil is the area under curve of blood concentration after soil being 
201 oral given (µg*h/L). These factors subscripted oral are equivalent values for oral dose of Pb 
202 acetate (Deshommes et al., 2012; Li et al., 2014).
203                                 (2)
204 The ratio of the concentration of Pb in individual endpoints (kidney, liver, femur and urine) 
205 after oral giving soil compare to oral giving Pb acetate is used to determine Pb RBA in soil 
206 using tissues. As defined in Equation 3 where Dosesoil is the Pb concentration of oral dose 
207 (µg/L) that is given, Csoil is the concentration of Pb in individual endpoints (kidney, liver, femur 
208 and urine) (µg/kg). These factors subscripted oral are equivalent values for oral dose of Pb 
209 acetate (Li et al., 2017).
210                                      (3)
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211 The exponential model is recommended to describe a repeated dose of the dose-response AUC 
212 curve for blood Pb, as shown in Equation 4 where a, b, and c are the terms of the mathematic 
213 equation used to describe the shape of the AUC curve, and Dose is the total daily administered 
214 dose of Pb (µg/kg BW /day) (U.S. Environmental Protection Agency, 2007c).
215     (4)
216 2.2 Measurement of Pb relative bioavailability (in vivo) 
217 A basic approach to estimate Pb RBA is using the in vivo method which is performed in a 
218 biological system and where the results can be extrapolated to humans (Weis and LaVelle, 
219 1991). Rodents such as mice and rats are commonly employed to estimate Pb RBA, in addition 
220 to swine, minipigs and monkeys. Previous in vivo studies of Pb bioavailability using various 
221 source of contaminated soils are shown in Figure 3 and Table 1. Swine have been employed in 
222 tests for assessing various sources of Pb contaminated soils, such as from mining, smelters, 
223 small arm ranges, incinerators, residential, and spiking soils (Bannon et al., 2009; Juhasz et al., 
224 2009; Denys et al., 2012; Wijayawardena et al., 2014). For all source of soils, the swine model 
225 shows both the highest (140% for small arm range) and lowest (0.75% for mining soils) Pb 
226 RBA values among all animal models (Schroder et al., 2004; Bannon et al., 2009). Compared 
227 to swine, small animals (rats and mice) are economic and also have been widely used in tests 
228 for assessing soils from in mining, smelters, gasworks, shooting ranges, farmland, and house 
229 dust (Ruby et al., 1996; Smith et al., 2011a; Li et al., 2014; Li et al., 2015). Lead RBA from 
230 the rats and mice models ranged from 7% to 89% for all source soils and from 7% to 36% for 
231 mining soils, which were smaller ranges compared to that from the swine model (Smith et al., 





235 Figure 3 Lead bioavailability of various source soils in different animal studies. The central 
236 mark on each boxis the median with the edges of the 25th and 75th percentiles. The whiskers 
237 extend to the most extreme data points not considered outliers. Outliers were not plotted in our 
238 study. The whiskers extend to the most extreme data points not considered outliers. Outliers 
239 were not plotted in our study.
240 References: (Freeman et al., 1992; Ruby et al., 1996; Casteel et al., 1997; Hettiarachchi et al., 2003; Schroder et 
241 al., 2004; Drexler and Brattin, 2007; Juhasz et al., 2009; Smith et al., 2011a; Denys et al., 2012; Li et al., 2015; Li 
242 et al., 2016) 
243
244 Various dosages of Pb were administrated to animals in different in vivo studies. Most of the 
245 dosages of Pb given in in vivo studies are designed by the body weight and daily ingestion of 
246 test animals (measured by the unit of µg Pb/kg BW day), and ranged from 50 µg Pb/kg BW 
247 day for swine (Denys et al., 2012) to 10700 µg Pb/kg BW day for mice (Li et al., 2015). This 
248 design is simulating the situation of both daily (repeat dosage) and accidental (single dosage) 
249 exposure for young children to Pb contaminated soils. Both swine and rats studies are given 
250 either repeat or a single dosage of Pb. For example, Pb dosages which ranged from 75 to 675 
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251 µg Pb/kg BW day were given to swine twice a day for 15 days to estimate Pb RBA (Casteel et 
252 al., 1997). Single dosages of Pb were given to mice (Smith et al., 2011a; Li et al., 2014) in most 
253 studies, this may be because mice have a relatively smaller body mass (BW = 20-25 g) and 
254 only limited blood samples are available. The only repeat dosage applied on mice (BW = 20-
255 22g) is from (Li et al., 2016) where samples were collected from kidneys rather than blood. 
256 Both fasting and fed states are employed in previous studies, and the fasting state is more 
257 popular because this is equivalent to the situation where children and babies are prone to ingest 
258 soils when they feel hungry (U.S. Environmental Protection Agency, 2007a). For the 
259 biomarkers, swine offer more choices to estimate Pb RBA via blood, liver, kidney, bone, femur, 
260 and urine (Casteel et al., 2006; Bannon et al., 2009; Denys et al., 2012). Rats and rabbits can 
261 also offer various biomarkers such as blood, liver, kidney, and bone for estimating Pb RBA 
262 (Ruby et al., 1993; Hettiarachchi et al., 2003). Mice offer only limited blood, again, due to their 
263 small body mass (Smith et al., 2011a; Li et al., 2014).
264
265 Weis et al. (1995) initiated a juvenile swine model experimental procedure for assessing oral 
266 BA from soils, which was further developed by Casteel et al. (2006) and applied to various 
267 soils (U.S. Environmental Protection Agency, 2007a; Bannon et al., 2009). The swine model 
268 is recommended to estimate Pb RBA, because its accelerated metabolism offers better 
269 simulation of the process of an infant’s and child’s growth and development (Moughan et al., 
270 1991; Casteel et al., 2006; U.S. Environmental Protection Agency, 2007a). Moreover, it obtains 
271 more biomarkers than other models. 
272
273 A wide range of Pb RBA suggested a significant influence from the soil type and soil properties 
274 to Pb RBA, indicating that the IEUBK model may over- or under- estimate Pb RBA in some 
275 cases. For example, Casteel et al. (1997) tested Pb RBA using swine model on two soils from 
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276 mining sites, and Pb RBA was estimated from the biomarkers of kidney, liver, and bone after 
277 15 days of experiments. Their results showed Pb RBA of the two tested soils are 63% and 64%, 
278 respectively, which were slightly higher than 60% (the value based on the IEUBK model from 
279 US EPA); However, in another study, Pb RBA tested by swine models on soils from mining 
280 sites showed a wider range from 0.75% to 105% (Schroder et al., 2004; Casteel et al., 2006; 
281 Denys et al., 2012). A similar performance was found from studies using rats and mice models 
282 either on soils from mining sites or from other sources (Hettiarachchi et al., 2003; Smith et al., 
283 2011a; Li et al., 2015).
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284 Table 1 In vivo studies on Pb contaminated soil/dust
Soil type Pb concentration 
range (mg/kg)
Specimen and biomarker Dose, period, state RBA (%) Reference
Mining 4482-40214 Swine (5 weeks age, BW = 9.5 ± 1.2 kg), 
kidney/liver/bone/urine  
50-4000 µg Pb/kg BW day, 14 days, 
fasting
8.25-58.67b (Denys et al., 2012)
1270-14200 Swine (5-6 weeks age, BW = 8 - 11 kg), 
blood/liver/kidney/femur
      15 days, fasting 6-105 (Casteel et al., 2006)
1270-14200 Swine (5-6 weeks age, BW = 10 ± 12 kg), 
blood/liver/kidney/bone 
15 days, fasting 0.75-97.75 (Schroder et al., 2004)
3900 Rabbits (BW = 2.1 kg), blood/liver/kidney/bone 2.0 ± 0.02 g Pb/kg BW, 36 hour, fasting 9 (Ruby et al., 1993)
3908-10230 Rats fed 8.7-36 (Ruby et al., 1996)
200-6330 Minipigs (10 weeks age, BW = 4.8 kg), 
kidney/liver/bone/urine
500 µg Pb/kg BW day, 28 days, fasting 17-63 (Marschner et al., 2006)
810, 3908 Rats (7-8 weeks age), blood/liver/ bone 30 days, fed 8.95, 13.57 (Freeman et al., 1992)
2924 Human Fast and fed 26.2(fast), 2.52 
(fed)a
(Maddaloni et al., 1998)
3870, 14200 Swine (BW = 8-9 kg), kidney/liver/bone 75, 225 and 675 µg Pb/kg BW day, 15 
days, fasting
63, 64 (Casteel et al., 1997)
516-4163 Mice (BW = 20-25 g), blood 2150 -10700 µg Pb/kg BW, 48 hour, 
fasting
7-26 (Li et al., 2015)
Smelter 1388, 2090 Rats 35, 41 (Ruby et al., 1996)
1460-30155 Swine (5 weeks age, BW = 9.5 ± 1.2 kg), 
kidney/liver/bone/urine  
50-4000 µg Pb/kg BW day, 14 days, 
fasting
32.25-94.5b (Denys et al., 2012)
536-3200 Mice (BW = 20-25 g), blood 48 hour, fasting 10-63 (Smith et al., 2011a)
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2154 Rats blood/liver/kidney/bone 15 days, fed 35.5c (Hettiarachchi et al., 2003)
250-25329 Mice (BW = 20-25 g), blood 2150 -10700 µg Pb/kg BW, 48 hour, 
fasting
30.8-84.3 (Li et al., 2015)
237-6330 Swine (6-8 weeks age, BW = 20-25 kg), blood 5 days, single dose, fasting 17-63e (Juhasz et al., 2009)
Small arm range 4503-23409 Swine, blood/liver/kidney/femur 15 days 77-140c (Bannon et al., 2009)
Gaswork 1343 Mice (BW = 20-25 g), blood 48 hour, fasting 43 (Smith et al., 2011a)
Shooting range 576, 1801 Mice (BW = 20-25 g), blood 48 hour, fasting 85, 89 (Smith et al., 2011a)
Dust  29-738 Mice (BW = 18-20 g), blood 340-6220 µg Pb/kg BW, 48 hour, 
fasting
29.1-60.1 (Li et al., 2014)
1693-6799 Children 11.25-21.48d (Oliver et al., 1999)
Incinerator and 
residential
646-3905 Swine (6-8 weeks age, BW = 20-25 kg), blood 5 days, single dose, fasting 10.1-19.1 (Juhasz et al., 2009)
Urban soil 12.6-1198 Female mice (BW = 20-22 g), kidney 10 days, repeat dose, fasting 17.3-86.6 (Li et al., 2016)
Farming 215-1543 Mice (BW = 20-25 g), blood 2150 -10700 µg Pb/kg BW, 48 hour, 
fasting
51.4-60.5 (Li et al., 2015)
Spiking and 
aging soils 
1500 Swine (BW = 20-25 kg), blood 5 days, single dose, fasting 34-59 (Wijayawardena et al., 2014)
285 a: ABA; b: average of tissue point RBA (kidney, liver, bone, urine); c: average of blood RBA and tissue point RBA (kidney, liver, bone); d: blood Pb level of children; e: data from (Juhasz et al., 
286 2009); BW: body weight;
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287 2.3 Uncertainties in measuring Pb relative bioavailability
288 A range of measurement uncertainties exists for Pb RBA determination. Early human 
289 experiments were conducted using traced Pb to identify absorption mechanisms for soluble Pb 
290 and interactions with food (James et al., 1985; Mushak, 1991). The only assay of Pb RBA 
291 performed on humans (adults) involved ingestion of Pb contaminated soils (Maddaloni et al., 
292 1998). This is a significant assay as it was carried out directly on humans; however, there are 
293 still some uncertainties because the digestive adsorption system of adults’ is different from that 
294 of children and babies, and children and babies are of particular concern. 
295
296 More in vivo experiments have been conducted using young animals, including swine, rats, 
297 mice and rabbits, using various experimental designs. A major source of concern in in vivo 
298 models is the intra-species and inter-species uncertainties. The intra-species uncertainties, 
299 including animal age, development stage, feeding behaviour, absorption rate, and digestion 
300 processes, can influence the Pb RBA results. The inter-species uncertainties, including the 
301 difference between the digestive systems of animals and children/babies result in uncertainties 
302 when directly extrapolating measured Pb RBA to children/babies. 
303
304 Several of these uncertainties relating to inter- and intra- species are reported. Compared to 
305 human stomachs, rodent stomachs have a smaller glandular region and less surface area for 
306 parietal cells to secreting acid (Weis and LaVelle, 1991). The gastrointestinal pH value of 
307 rabbits is significantly lower than that of humans (Merchant et al., 2011). The maturity of a 
308 rat’s small intestine is weaning, which is different to a baby (Weis and LaVelle, 1991). 
309 Moreover, a rat has a relatively smaller surface area of small intestine than that of humans 
310 (about 1/5), which could decrease Pb RBA (Weis and LaVelle, 1991). Although it is reported 
311 that the juvenile swine could be a better alternative for predicting digestive and absorption 
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312 processes for infants, as there are many similarities between them, including gastric 
313 hydrochloric acid (HCl) and protease secretion; small intestine configuration; limited digestive 
314 capacity and gut maturity (Moughan et al., 1992; Heath et al., 2003), significant differences 
315 also exists. For example, the capacity of a piglet’s stomach is 2 times higher than that of infants 
316 in the same body weight (5.75kg), which are 260 cm3 and 130 cm3, respectively (Moughan et 
317 al., 1991). The above differences could lead to significant differences for the estimation of Pb 
318 RBA and introduce uncertainties while extrapolating Pb RBA from an animal study to human 
319 health.
320
321 In in vivo studies, the Pb RBA can be also  affected by feeding state (fast or fed), dosage and 
322 frequency of dose (single or repeat feeding) (Weis et al., 1995). A rat based study showed that 
323 the uptake of PbAc reduced about 50% when Pb was fed with food, compared to the fasting 
324 state (U.S. Environmental Protection Agency, 2007a). In another study, a higher stomach pH 
325 of 3.9 was obtained for a mouse in the fasting state than 3.2 in a fed state  (McConnell et al., 
326 2008). In another aspect, only rabbits present a significantly lower pH of 1.6 in a fed state 
327 compared to humans (Merchant et al., 2011). The fasting state was employed in most of the 
328 studies to simulate the situation of accidental oral ingestion for children (Casteel et al., 2006; 
329 Denys et al., 2012; Li et al., 2014).
330
331 The daily ingested rate of soil and dust for infants and toddlers via normal hand-to-mouth 
332 activities (no pica) is about 100 mg/day (Brunekreef et al., 1981; Mushak, 1991), and is 135 
333 mg/day for late infants and toddlers based on the US EPA IEUBK model (P. Mushak, 1998). 
334 Therefore, the dosages for in vivo testing should be considered to be representative of children’s 
335 exposure (Ruby et al., 1993). In past in vivo studies, various doses of Pb were given to test 
336 animals. For example, for the swine with a similar age (5-6 weeks old), Casteel et al. (2006) 
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337 gave a dose of 75-675 µg Pb/kg bodyweight/day, while Denys et al. (2012) gave a dose of 50-
338 4000 µg Pb/kg bodyweight/day. The mice model was administered using a higher dose of Pb. 
339 For example, Li et al. (2015) gave a dose of 2150-10700 µg Pb/kg bodyweight/day. In fact, the 
340 design of the dosages for in vivo studies should consider not only being the representative of 
341 children’s exposure but also the detection limitation. Finally, some studies use Pb RBA 
342 measured from blood (Li et al., 2014) while some of them using point estimation using samples 
343 from  bone, urine, liver, and kidney (Denys et al., 2012).
344
345 In conclusion, uncertainties in in vivo studies are mainly from the design of experiments, such 
346 as dosages, fast or fed state, frequency of dose given, inter- and intra-species differences, and 
347 extrapolation from test animals to humans, especially children. The swine model was 
348 demonstrated to be the best model to estimate Pb RBA for the exposure of Pb to children; 
349 however, it is more expensive than the other models such as rats, mice and monkeys. 
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350 2.4 Pb bioaccessibility (in vitro)
351 Although using in vivo models to estimate RBA has a number of potential benefits with less 
352 uncertainties, the application of in vivo methods is largely limited due to its expense- and time-
353 consumption (U.S. Environmental Protection Agency, 2007a). On a large and wide scale, the 
354 in vivo methods are not therefore suitable to estimate site-specific Pb RBA (Li et al., 2015). 
355 The in vitro methods for determining the bioaccessible portion of Pb are proposed, although 
356 these methods may provide a conservative result (Paustenbach, 2000). The currently used in 
357 vitro methods are summarized in Table 2. Mainly two types of in vitro methods were developed 
358 to measure Pb BAc including physiological based and non- or partially physiological based. 
359 The physiological based tests simulate the biochemical conditions of a human’s gastrointestinal 
360 environment to assess the leaching of Pb from soil/dust (Ruby et al., 1996; Oomen et al., 2002; 
361 Wragg and Cave, 2003; Oomen et al., 2006). Such trials were originally from the assessment 
362 of BA iron in food for nutrition studies (Miller et al., 1981). The non- or partially physiological 
363 based methods use various chemicals to extract bioaccessible Pb from soil/dust (Drexler and 
364 Brattin, 2007). Both of the two types of analysis can involve either a single extraction step or 
365 multiple extraction steps simulating different physiobiological phases.
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366 Table 2 Summary of current in vitro models for estimating Pb bioaccessibility
Physiological based in vitro models Non physiological based in vitro 
models
UBM: the unified BioAccessibility Research Group Europe 
(BARGE) method (Denys et al., 2012)
RBALP: the Relative Bioavailability 
Leaching Procedure (Drexler and Brattin, 
2007)
PBET: a Physiologically Based Extraction Test (Ruby et al., 
1996)
SBRC (Gastric): the Solubility 
Bioaccessibility Research Consortium assay 
(Juhasz et al., 2009)
RIVM: the In Vitro Digestion Model of RIVM (The 
Netherland) (Oomen et al., 2003)
IVG: in-Vitro Gastrointestinal Method (Schroder et al., 2004)
DIN: The German DIN model applied
by the Ruhr-Universita¨t Bochum (RUB, Germany) (Oomen 
et al., 2002)
TIM: The Gastrointestinal Model by TNO (The Netherlands) 
(Oomen et al., 2002)
SHIME: Simulator of Human Intestinal Microbial Ecosystems 
of Infants (Oomen et al., 2002)
SBRC (intestinal): the Solubility Bioaccessibility Research 
Consortium assay (Juhasz et al., 2009)
367
368
369 After years of development and validation, six in vitro (PBET, UBM, RIVM, IVG, RBALP 
370 and SBRC) models are widely used to measure Pb BAc. The six in vitro models vary in key 
371 parameters (e.g. pH, reaction time, mixing mode, mixing speed, solid/liquid ratio) but not in 
372 temperature (37°C) and soil particle size (< 250 µm). A summary of key parameters in these 
373 six in vitro methods is shown in Table 3. The detailed procedure can be found elsewhere 
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374 (Hettiarachchi et al., 2003; Schroder et al., 2004; Oomen et al., 2006; Drexler and Brattin, 2007; 
375 Juhasz et al., 2009; Denys et al., 2012). 
376 Table 3 Key parameters in six in vitro methods
Model Phase Duration pH Mixing/speed S/L ratio (g/ml) pH 
monitor
RBALP
(Drexler and Brattin, 2007)
G 1 1.5 Rotation, 30 rpm 1/100 Yes
oral 10 s 6.5 Hand shake, 10s 1/15 No
G 1 h 1.2 1/37.5 Yes
UBM 
 (Denys et al., 2012)
I 4 h 6.3
Rotation
1/97.5
G 1 h 2.5 1/100 NoPBET   
(Ruby et al., 1996)




G 1 h 1.8 1/150 NoIVG
 (Schroder et al., 2004)
I 1 h 5.5
Stirring
1/150
G 1 h 1.5 1/100 YesSBRC 
(Juhasz et al., 2009)
I 4 h 6.5
Rotation, 40 rpm
1/100
Oral 5 mins 6.5 1/15 or 1/150 No
G 2 h 1-2 1/37.5 or 1/375 Yes
RIVM 
(Oomen et al., 2006)
I 2 h 5.5-6.5
Rotation, 55 rpm
1/96 or 1/958 Yes
377 G: gastric phase; I: intestinal phase; h: hour; s: second; S:L ratio: solid:liquid ratio. For full form of the 
378 abbreviation please refer to Table 2.
379
380
381 Pb BAc varied depending on soil types and the different in vitro models employed. Van de 
382 Wiele et al. (2007) compared the PBET, RIVM (0.6) and RIVM (0.06) models for the Bunker 
383 Hill soil, and found Pb BAc values were 13%, 31.8% and 47.4% for the fasting state, and 
384 21.8%, 23.9% and 38.8% for the fed state, respectively. In addition, the RBALP, UBM, PBET, 
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385 SBRC, IVG models were employed to estimate Pb BAc in peri-urban soils. Estimation using 
386 the RBALP and IVG models were more conservative than that using the other models (Juhasz 
387 et al., 2013b).  Moreover, Li et al. (2014) estimated Pb BAc  in house dusts using different in 
388 vitro models (UBM, SBRC, IVG, PBET), which showed SBRC has the highest gastric BAc 
389 value, followed by IVG, DIN and PBET, while PBET has a higher intestinal BAc value than 
390 the other models.
391
392 A summary of available Pb BAc data is presented for different sources in Table 4. The Pb 
393 concentration in smelter soils ranged from 5.2 to 150000 mg/kg, higher than that for mining 
394 soils ranging from 59 to 77007 mg/kg. For all sources, the Pb BAc ranged from 0.49% to 105% 
395 for gastric phase (G-phase) and from 0.03% to 73% for intestinal phase (I-phase), respectively 
396 (note: relative BAc is not considered in this case). For the soil from mining and smelter sites, 
397 the Pb BAc of G-phase ranged from 1.4% to 95% and 6.66% to 96%, respectively. Rieuwerts 
398 et al. (2000) also reported that Pb concentration and Pb solubility in smelter soils and dust is 
399 higher than that in mining and other soils and dusts. 
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400 Table 4 Lead bioaccessibility estimated using in vitro methods for different sources of soils.
Source In vitro model Pb concentration (%)     BAc (%)
Gastric                   Intestinal 
Reference
Mining UBM 4482-40214 10.6-82a 9.2-90a (Denys et al., 2012)
RBALP 1270-14200 6-90 - (Casteel et al., 2006)
IVG 1270-14200 1.4-64.4 0.03-3.23 (Schroder et al., 2004)
PBET (S/L=1:40)b 3900 4 NA (Ruby et al., 1993)
PBET (S/L=1:250) 3908-10230 9.5-49 1.1-14 (Ruby et al., 1996)
IVG 237-6330 35-70.7 2.7-6.8 (Marschner et al., 2006)
RIVM (0.06)c 1270-11700 3.7-82.6 1.1-65.8 (Oomen et al., 2006)
RIVM (0.6)d 1270-11700 3.9-70.9 1.9-49.8 (Oomen et al., 2006)
RIVM (0.6g)d 2141-77007 15-56 5-25 (Denys et al., 2007)
RIVM (0.6g)d 623-5967 11-66 NA (Oomen et al., 2002)
RBALP 56-91 - (Oomen et al., 2002)
PBET (pH=1.3) 59-12100 4-54 NA (Bruce et al., 2007)
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(Smith et al., 2011b)
(Yang and Cattle, 2015)
Smelter UBM 1460-30155 40.5-82.6a 33.4-90a (Denys et al., 2012)
SBRC 536-1489 34-96 1.6-16.3 (Smith et al., 2011a)
PBET (pH=2.5) 1200-3500 25-43 7-12 (Berti and Cunningham, 1997)
PBET (pH=2.5) 56.3-9585 6.66-22.43 0.77-9.78 (Finžgar et al., 2007)
RBALP 390-150000 14.34-88.45 - (Bosso and Enzweiler, 2008)
PBET (Ph=1.7) 390-150000 10.36-78.88 NA (Bosso and Enzweiler, 2008)
UBM 984e 62e 32e (Roussel et al., 2010)
RBALP 5.2-6945 21.3-87.4 - (Lamb et al., 2009)
Small arms 
range
RBALP 4503-23409 83-100 - (Bannon et al., 2009)
Gasworks SBRC 1343 45 8.8 (Smith et al., 2011a)
Shooting range SBRC 576, 1801 94, 99 16.5, 17.3 (Smith et al., 2011a)
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SBRC 576-3026 50-105 2.2-11.1 (Smith et al., 2011b)

















(Li et al., 2014)
(Li et al., 2014)
(Li et al., 2014)
(Li et al., 2014)
PBET (pH=2.5, S/L=1:200) 50.3-468 11.6-36.3 2-22 (Turner and Ip, 2007)
Pottery RIVM (0.6g)d 50-11000 NA 0.3-73 (Oomen et al., 2003)
Paint PBET (pH=2.5, S/L=1:100 to 1:143) 16-11110 0.49-18.24 0.49-5.78 (Turner et al., 2009)
Incinerator RBALP 30.1-977 26.94-89.36 - (Madrid et al., 2008)
SBRC 2885-3905 60.9-64.1 1.2-2.3 (Juhasz et al., 2009)
Residential SBRC 646, 765 35.7, 61 2.1, 2.7 (Juhasz et al., 2009)









(Reis et al., 2014)
(Li et al., 2016)
401 a: relative bioaccessibility, PbAc as reference; b: S/L=solid liquid ratio; c: 0.06g soil per digestion tube; d: 0.6g soil per digestion tube; e: mean of 27 soils. NA: data not available; 
402 -: not applicable. For full form of the abbreviation please refer to Table 2.
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403 2.5 Key parameters in in vitro models
404 The parameters used in in vitro methods could also influence the BAc results. The key 
405 parameters are listed in Table 5. Here we summarize and articulate the parameters during 
406 various in vitro methods to understand influencing factors for measurement of BAc. 
407 2.5.1 pH
408 The pH value is more sensitive than other parameters as Pb solubility is highly dependent on 
409 pH — Pb BAc decreased with an increase in pH (Ellickson et al., 2001; U.S. Environmental 
410 Protection Agency, 2007c; Juhasz et al., 2009). The pH of human G-phase ranged from 1 to 4 
411 for the fasting condition (Washington et al., 2000), and a range of 1.0 to 2.5 is employed to 
412 investigate Pb BAc (Ruby et al., 1993; Oomen et al., 2003; Bruce et al., 2007; Drexler and 
413 Brattin, 2007). It is critical to control the pH during the G-phase extraction (Wragg et al., 2011). 
414 Previous studies compared Pb BAc from extractions with or without pH control. For example, 
415 Oliver et al. (1999) reported that when the pH was monitored and maintained at 1.3, the 
416 measured Pb BAc for house dust was higher (26-46%) than that without pH control (20-30%). 
417 Furthermore, Ruby et al. (1996) measured the BAc of G-phase for 8 contaminated soils from 
418 various sources (mining, smelter, residential and tailing sites) and showed that the Pb BAc of 
419 G-phase at pH 1.3 is 2-4x higher than that at pH 2.5. A stable pH control during a G-phase test 
420 could provide more conservative results and it is critical to simulate acidic conditions. 
421
422 2.5.2 Mixing mode
423 The mixing mode has a significant effect on measurement of  Pb BAc since the dissolution of 
424 Pb bearing minerals/materials was controlled by the mixing mode through transport 
425 mechanisms, (FaciesRuby et al., 1999). Several mixing modes have been used in in vitro 
426 assays, including gas mixing, end-over-end rotation and shaking. The wrist-action shaker was 
427 initially applied by Ruby et al. (1993) on an in vitro assay. This assay was modified three years 
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428 later and is well known as the PBET model, where the argon (Ar) gas was used to mix Pb 
429 particles and the extraction solution (Ruby et al., 1996). This mixing mode is effective and 
430 aggressive which may overestimate the Pb BAc (Ruby et al., 1996). The shaking mode is 
431 effective while it may underestimate the Pb BAc as more particles may be adhered to the 
432 bottom and walls of the tube which reduces the effective contact surface between soil particles 
433 and solution (Drexler and Brattin, 2007; U.S. Environmental Protection Agency, 2007a). The 
434 end-over-end rotation is recommended as it maximizes the contact area of soil particles and 
435 digestive juices, and minimises contamination from interacting devices (Drexler and Brattin, 
436 2007). A comparison study of shaking and end-over-end rotation modes using the RBALP 
437 method showed that the mean and median Pb BAcs of end-over-end rotation mode (66.8% and 
438 77.1%, respectively) is higher than that of shaking mode (51.3% and 52.7%, respectively), and 
439 a significant difference was obtained between the two modes (p = 0.016, paired t-test) (Yan et 
440 al., 2016) .
441
442 2.5.3 Solid:liquid ratio
443 Numerous solid:liquid (S:L) ratios have been applied in various assays, and the S:L ratio can 
444 also significantly impact Pb BAc. A high S:L ratio could reduce Pb dissolution in the extractant 
445 and result in an increase in  pH, therefore leading to an underestimate of Pb BAc (Oomen et 
446 al., 2006; Drexler and Brattin, 2007). Sorenson et al. (1971) found that the S:L ratio influenced 
447 dissolution of metals in extraction procedures in the range of 1:5 to 1:25, most likely due to 
448 diffusion-limited dissolution kinetics. Ruby et al. (1996) reported Pb BAc at a S:L ratio of 
449 1:100 was higher than that at a S:L ratio of 1:10, which are 9.5% ~ 35% and under 6%, 
450 respectively. Yang et al. (2003) reported a 10% increase in BAc from S:L ratios of 1:40 to 
451 1:100. Hamel et al. (1998) reported when the S:L ratio changed from 1:100 to 1:5000, Pb BAc 
452 increased obviously for the test soils. Meanwhile, Van de Wiele et al. (2007) have found a 
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453 significant difference in Pb BAc derived from the RIVM model (gastric phase) at S:L ratios of 
454 1:100 and 1:1000; However a very low S:L ratio may add difficulty in analysis and lead to 
455 poorer reproducibility and more uncertainties (Oomen et al., 2006). A S:L ratio of 1:100 was 
456 recommended and care must be taken when selecting the S:L ratio for testing soils containing 
457 high concentrations of Pb (Drexler and Brattin, 2007). 
458
459 2.5.4 Comparisons of in vitro models
460 As discussed above, the pH and S:L ratio can significantly influence Pb BAc, and end-over-
461 end rotation is a better mixing mode (Table 5). Although the RBALP model is non-
462 physiologically based, has no I-phase, and may overestimate Pb BAc for some testing soils 
463 (Juhasz et al., 2013b), it monitors pH during the G-phase, and is the most cost-effective, 
464 simplest and fastest method with good validation using the swine model and statistical analysis. 
465 The SBRC model has a similar procedure and the same components for G-phase as the RBALP 
466 model, and has an extra I-phase which can be used to indicate Pb RBA (Juhasz et al., 2009). 
467 The UBM method is fully physiologically based, validated using the swine model and 
468 statistical analysis, and has pH control during G-phase, which are all favourable for Pb BAc 
469 measurement. It has a relatively complicated procedure and may not be suitable for some soils 
470 (Denys et al., 2012; Yan et al., 2016); however, it can provide a good estimation of Pb BAc. 
471 The RIVM model is from the RIVM group in the Netherland, and has a very similar procedure 
472 and components as the UBM model (Oomen et al., 2003). The PBET model offers a scientific 
473 foundation for the other in vitro models; however, it has no pH monitor for the G-phase, and 
474 was modified to several different procedures, including different pHs for the G-phase (1.5 to 
475 2.5), different components for gastric fluids and different mixing modes (shaking, argon gas) 
476 (Ruby et al., 1993; Ruby et al., 1996; Hettiarachchi et al., 2003; Li et al., 2015). In conclusion, 
477 for a non-physiologically based method, the RBALP method is recommended and the UBM 
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478 method is recommended for a non-physiologically based method and fully physiologically 
479 based method. 
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480 Table 5 Comparison of five commonly used in vitro methods







RBALP R 30rpm Yes * 1 h 1-50000 mg/kg, only G-phase applied
UBM R 40rpm Yes **** 5 hours Limitation: G-phase may not suit for some high Pb 
concentration soils which contain high proportion of  
bioaccessible Pb.
RIVM (0.6) R 55rpm Yes **** 4 hours Limitation: G-phase may not suit for some high Pb concentration soils which contain high proportion of  
bioaccessible Pb.
RIVM (0.06) R 55rpm Yes **** 4 hours Limitation: may bring poor reproducibility and more 
uncertainties. 
SBRC R 40rpm No ** 5 hours
PBET Argon gas 
or shaking 
No *** 2 or 5 hours




483 2.6 Correlations between in vivo and in vitro methods 
484 Although in vitro methods have been proposed as the alternative method to in vivo RBA, strong 
485 and reliable correlations between the in vivo and the in vitro methods (IVIVC) are limited. 
486 Several mathematical models, such as linear, power and exponential models have been 
487 discussed and the linear regression model is recommended as it can take into account all 
488 measurement errors (U.S. Environmental Protection Agency, 2007a). Various studies to 
489 validate IVIVC have been conducted by researchers, which are summarised in Table 6. Ruby 
490 et al. (1996) measured Pb BAc using the PBET method for seven mining and residential soils 
491 and reported a correlation of Pb BAc based on G-phase and Pb RBA as determined using rats 
492 models (Pb RBA = 1.4*Pb BAc + 3.2, r2 = 0.93). A later study of Pb IVIVC using the PBET 
493 method and Pb RBA (in vivo rats model) was carried out by Hettiarachchi et al. (2003), and 
494 both the G-phase and I-phase of PBET can predict Pb RBA. Schroder et al. (2004) measured 
495 Pb BAc using the IVG method and Pb RBA using the in vivo swine model, and found an 
496 IVIVC: Pb RBA = 0.39*Pb BAc (G-phase) + 2.97, r2 = 0.86. Oomen et al. (2006) studied 
497 IVIVC using the RIVM method and the in vivo swine model, and found the IVIVC based on 
498 both G-phase and I-phase are similar. Drexler and Brattin (2007) reported that the RBALP 
499 model is simple, cost-effective, reliable and provides the best estimate of Pb RBA as 
500 determined using an in vivo swine model (Pb RBA = 0.878*Pb BAc - 0.028, r2 = 0.924, p < 
501 0.001). 
502
503 The IVIVC may vary (slope, r2) depending on the in vitro and in vivo models applied, and the 
504 source of soil varying with soil properties, Pb concentration, and other heavy metals such as 
505 Fe and Ca which may have competitive adsorption to Pb in soil. As shown in Table 6, the 
506 RBALP, UBM, RIVM, PBET, SBRC and IVG were used to predict Pb RBA. For the same in 
507 vitro model used to predict Pb RBA in different sources of contaminated soils, various slope 
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508 and r2 for IVIVC were obtained. For example, Drexler and Brattin (2007) and Smith et al. 
509 (2011a) validated Pb BAc (RBALP) using swine and mice models, the slope and r2 are 0.87, 
510 0.69 and 0.924, 0.78, respectively. Even for the same in vitro and in vivo model applied on a 
511 different source of Pb contaminated soils, different slope and r2 for IVIVC were obtained. For 
512 example, the SBRC model and the in vivo mice model were used for dust and 
513 mining/smelter/farming soils, their IVIVC slope and r2 are 0.61, 0.40 and 0.68, 0.43, 
514 respectively (Li et al., 2014; Li et al., 2015). Moreover, for the same source soils, the IVIVC 
515 based on the same in vivo model (swine) and different in vitro models (IVG and RIVM), 
516 resulted in different slope and r2 values (Schroder et al., 2004; Oomen et al., 2006). Wragg et 
517 al. (2011) suggested that the IVIVC slope should between 0.8 and 1.2, y-intercept not 
518 significantly different from 0 and r2 should not below 0.6. Juhasz et al. (2013a) stated the same 
519 requirements for the slope (0.8 to 1.2), and similar r (above 0.8). Although there are more than 
520 30 IVIVCs based on both G-phase and I-phase using various models and soils/dusts (as shown 
521 in Table 6), only a small fraction of IVIVCs meet the requirements proposed by Wragg  (7 of 
522 18 IVIVCs of G-phase and 3 of 15 IVIVCs of I-phase, respectively). 
523
524 Although the intestine is the main place of Pb desorption, a detailed investigation of Pb 
525 speciation in artificial human digestive fluid, Oomen et al. (2003) concluded that the amount 
526 of free Pb2+ in I-phase is negligible, and most of the Pb in soil particles was in dynamic 
527 equilibrium with soluble Pb presenting as Pb-phosphate and Pb-bile complexes. The 
528 concentration of Pb in the aqueous phase is impacted by precipitation or adsorption onto non-
529 digestible and compatible particles (Deshommes et al. 2012), and consequently, elevated pH 
530 in I-phase directly reduces Pb BAc. Studies by (Medlin, 1997) and (Drexler and Brattin, 2007) 
531 have indicated that no small intestinal phase (pH∼7) is required for the RBALP as the gastric 
532 phase showed acceptable correlation with the in vivo results. As shown in Table 6, 11 of 13 
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533 studies using both gastric and intestinal phases to generate IVIVC showed that the slope of 
534 IVIVC from gastric phase is better than that from intestinal phase. This indicated that the gastric 
535 phase has on average a more reliable IVIVC than the intestinal phase. 
536
537 Challenges still exist to predict Pb RBA using in vitro models due to various uncertainties 
538 deriving from interspecies extrapolation, different soil types and in vitro methods. Thus reliable 
539 in vivo and in vitro models are desired with minimised uncertainties and which provide an 
540 accurate estimation of Pb RBA.
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541 Table 6 Validation of in vitro methods using animal models (swine, rats, mice)
Soils source                   
(sample number)




Key parameters used in vitro models
S/L ratio in              G-phase                I-phase  
G-phase (g/ml)    
IVIVC Reference
EPA region VIII 
(n=19) Swine/blood RBALP No 1/100 1h, pH1.5 No
G: y = 0.87x - 0.028. r2 = 0.924, p < 
0.0001
(Drexler and Brattin, 
2007)
Soils                  
(n=12) Mice/blood RBALP No 1/100 1h, pH1.5 No G: y = 0.69x + 30.21. r
2 = 0.78 (Smith et al., 2011a)
Jasper Yard soils, 
residential soils, 






1/37.5 1h, pH1.2 4h, pH6.3 G*: y = 0.78x, r
2 = 0.61                          










1/37.5 1h, pH1.2 4h, pH6.3 G*: y = 1.86x + 1.10,r
2 = 0.93, p < 0.01   
I*: y = 1.09x + 1.01,r2 = 0.89, p < 0.01 (Denys et al., 2012)
Soils                  
(n=12)














I*: y = 1.06x - 7.02, r2 = 0.88
G:  y = 0.83x + 2.28, r2 = 0.61
(Smith et al., 2011a)
(Li et al., 2016)
 Incinerator & 
urban soils                    
(n=5)   
Swine/blood SBRC No 1/100 1h, pH1.5 4h, pH6.5 I*: y = 0.58x + 1.98, r2 = 0.53 (Juhasz et al., 2009)
EPA Region VIII  
(n=15)  Swine/blood PBET No 1/111 1h, pH1.5 No G: y = 0.9x - 8.21. r
2 = 0.63. p < 0.001 (Medlin, 1997)
Mining&residential 
soils                    
(n=7)
Rats/blood PBET No 1/100 1h, pH2.5 4h, pH7.0 G: y = 1.4x + 3.2. r2 = 0.93 (Ruby et al., 1996)
Joplin soil          
(n=15)
Rats/blood, liver, 
kidney, bone PBET No 1/100 1h, pH2.0 4h, pH6.5
G: y = 0.82x + 11. r2 = 0.95                   
I: y = 1.87x + 12. r2 = 0.77




542 *: the relative BAc was applied in the IVIVC. IVIVC: correlation between in vivo and in vitro methods. G-phase/G: gastric phase; I-phase/I: intestinal phase. S/L=solid liquid 
543 ratio. For full form of the abbreviation please refer to Table 2.
EPA Region VIII 
(n=18)    Swine/blood IVG No 1/150 1h, pH1.8 4h, pH5.5 G: y = 0.39x + 2.97. r
2 = 0.86 (Schroder et al., 2004)
EPA Region VIII, 




pH 6.5 1/37.5 2h, pH1-2 2h, pH5.5-6.5
G*: y = 0.79x, r2 = 0.95                          
I*: y = 0.69x, r2 = 0.81 (Oomen et al., 2006)
EPA Region VIII, 




pH 6.5 1/375 2h, pH1-2 2h, pH5.5-6.5
G*: y = 1.08x, r2 = 0.68                             
I*: y = 1.16x, r2 = 0.66 (Oomen et al., 2006)
SBRC No 1/100 1h, pH1.5 4h, pH7.0 G: y = 0.61x + 3.15. r
2 = 0.68                       
I: y = 1.72x + 42. r2 = 0.15 (Li et al., 2014)
IVG No 1/150 1h, pH1.8 1h, pH5.5 G: y = 0.48x + 14.3. r
2 = 0.56                       
I: y= -0.57x + 51.6. r2 = 0.01
DIN No 1/50 2h, pH2.0 6h, pH7.0 G: y = 0.67x + 17.4. r
2 = 0.85                       
I: y = 6.9x + 36.9.  r2 = 0.38
Dust in 15 cities in 
China                
(n=12)
Mice/blood
PBET No 1/100 1h, pH2.5 4h, pH7.0 G: y = 0.69x + 20.2. r
2 = 0.52                       





1/37.5 (G) 1h, pH1.2 4h, pH6.3 G: y = 0.80x + 9.99. r
2 = 0.67                       
I: y = 1.26x + 47.8. r2 = 0.01
SBRC No 1h, pH1.5 1/100 4h, pH7.0 G: y = 0.40x + 14.0. r
2 = 0.43                       
I: y=-2.54x + 26.3. r2 = 0.21
IVG No 1h, pH1.8 1/150 1h, pH5.5 G: y = 0.77x + 6.36. r
2 = 0.55                       
I: y = 4.17x + 22.7.  r2 = 0.24
Farming, mining 
and smelter soils in 
China (n=12)
Mice/blood
PBET No 1h, pH 2.5 1/100 4h, pH7.0 G: y = 0.87x + 18.9. r
2 = 0.38                       
I: y = 2.38x + 29.6.  r2 = 0.20
(Li et al., 2015)
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544 As shown in Table 6, although many studies have been conducted for validating the 
545 correlation between in vivo and in vitro models, there are still many uncertainties 
546 as the slope of IVIVC ranged from 0.39 to 1.86 for the gastric phase and 0.57 to 
547 2.54 for the intestinal phase. A meta-analysis on the correlation showed a generic 
548 linear model based on the correlations from 5 commonly used in vitro models, 
549 which is (RBA (%) = (0.87 ± 0.16) × BAc + (4.70 ± 2.47)) (Dong et al., 2016; Yan 
550 et al., 2016). Even for the soils from the same source, the IVIVC based on the same 
551 in vivo model (swine) and different in vitro models (IVG and RIVM), results in 
552 different slope and r2 values (Schroder et al., 2004; Oomen et al., 2006). 
553 Furthermore, most of the IVIVCs were validated by the Pb BAc value from the G-
554 phase, some of the IVIVCs were also validated by Pb BAc both from the G-phase 
555 and I-phase, and some of the IVIVCs were only validated by relative Pb BAc values 
556 from the I-phase (Juhasz et al., 2009; Smith et al., 2011a). Moreover, Denys et al. 
557 (2012) use relative Pb BAc from both G-phase and I-phase to indicate Pb RBA and 
558 found significant correlations (G: y = 1.86x + 1.10, r2 = 0.93, p < 0.01, I: y = 1.09x 
559 + 1.01, r2 = 0.89, p < 0.01). All these uncertainties are largely because various soil 
560 properties and inter-species differences, as well as different in vitro methods. All 








Intra-species Variability using the same animals or human




Fast or fed state; single or repeat dose; dose of feeding; 





Various key parameters influencing Pb BAc
Operation Operation errors in experiment and analysis processes
Detection Limitation of detection for Pb in soils or soil solution
Application of 
in vitro models
One in vitro model may not suit for measuring Pb BAc for 
all source of soils
Validation of 
IVIVC
Limited data on validation of IVIVC
Soil type Soil types influence Pb concentration and soil properties, then affect Pb BA
Soil properties Influence of soil properties on Pb BA or BAc
Modelling Measurement and extrapolation errors
564 BA: bioavailability; BAc: bioaccessibility; IVIVC: correlation between in vivo and in vitro 
565 methods; RBA: relative bioavailability.
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566 3 Effect of soil properties on Pb bioavailability
567 Apart from the influence of measurement parameters on RBA/BAc, the soil 
568 properties can also have a significant influence on RBA/BAc. As discussed 
569 previously, the source of Pb contamination could result in different RBA/BAc, 
570 values and other soil properties, such as clay content, organic matter and oxides 
571 content can also cause different RBA/BAc. The following sections will focus on 
572 these aspects.
573
574 3.1 Source of Pb contaminated soil/dust 
575 Nature of Pb released in the extract varied depending on different sources of 
576 contamination. Pure mineral phases of native Pb in natural soils may occur as Pb 
577 sulfide (PbS), Pb sulfate (PbSO4), or Pb carbonate (PbCO3) (FaciesRuby et al., 
578 1999). In mining sites, Pb mineral may be encapsulated with other soil mineral 
579 grains, such as quartz. While in smelter sites, Pb minerals are often mixed with 
580 other pyrometallurgical waste materials and slags, and changed through various 
581 processes from different factories (FaciesRuby et al., 1999). All these changes are 
582 reported to influence Pb BA (Rieuwerts et al., 1998). Rieuwerts et al. (2000) 
583 reported that Pb concentration and solubility of soils from mining areas are lower 
584 compared to smelter urban areas. Moreover, the reactions of soil components like 
585 precipitation, adsorption, and degradation in the weathering process also changes 




588 Lead BA studies have been carried out on Pb contaminated soils from a great variety 
589 of sources. As summarized in Table 8, the most popular spot is mining soils, 
590 followed by smelter soils, small arms ranges, dust, shooting ranges, incinerators, 
591 residential, and gasworks. All this data is obtained by in vivo models such as those 
592 involving humans/swine/rats/mice/rabbits. As shown in Table 8 and Figure 4, soils 
593 from mining have the widest range of Pb concentration (200 to 40214 mg/kg), 
594 followed by smelter (536 to 30155 mg/kg), small arms ranges (4503 to 23409 
595 mg/kg), and dust (29 to 6799 mg/kg). Small arm ranges show the highest mean Pb 
596 concentration value, followed by mining soils, smelter soils, incinerator site, 
597 gasworks, dust, shooting range, and residential, which are 16305 mg/kg, 7641 
598 mg/kg, 3935 mg/kg, 3257 mg/kg, 2200 mg/kg, 1399 mg/kg, 1187 mg/kg and 706 
599 mg/kg, respectively. As shown in Figure 4, around 90% of the total Pb 
600 concentration values are in the range of 0-12500 mg/kg for all source of soils/dust, 
601 except for small arms ranges which have most data out of the range. 
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602 Table 8 Pb concentration and relative bioavailability ranges sorted by different 
603 sources 
Source Range of Pb concentration 
(mg/kg)






Mining 200-40214 0.75-105 42.23 40
Smelter 536-30155 10-94.5 49.3 42
Small arms ranges 4503-23409 77.3-139.9 108.9 109
Dust 29-6799 29.1-60.1 48.65 49.40
Shooting range 772-1602 85-89 87 87
Incinerator 2885-3905 13 -37.8 26.7 29.5
Residential/urban 
soils
12.6 -1198 17.3 – 86.6 48.2 48.7
Gasworks 2200 43 43 43
Farming 215-1543 51.4-60.5 57 57.8






608 Figure 4 Distribution of Pb relative bioavailability from various sources. The 
609 central mark on each boxis the median with the edges of the 25th and 75th 
610 percentiles. The whiskers extend to the most extreme data points not considered 
611 outliers. Outliers were not plotted in our study. The whiskers extend to the most 
612 extreme data points not considered outliers. Outliers were not plotted in our study.
613 Rreferences: (Freeman et al., 1992; Ruby et al., 1992; Ruby et al., 1996; Casteel et al., 1997; 
614 Maddaloni et al., 1998; Hettiarachchi et al., 2003; Schroder et al., 2004; Marschner et al., 2006; 
615 Drexler and Brattin, 2007; Madrid et al., 2008; Bannon et al., 2009; Smith et al., 2011a; Denys et 





619 Figure 5 Distribution of Pb relative bioavailability values in various sources of 
620 soils and dusts 
621 References: (Freeman et al., 1992; Ruby et al., 1996; Casteel et al., 1997; Hettiarachchi et al., 
622 2003; Schroder et al., 2004; Drexler and Brattin, 2007; Juhasz et al., 2009; Smith et al., 2011a; 
623 Denys et al., 2012; Li et al., 2015; Li et al., 2016)
624
625 All the Pb RBA data collected are shown in Figure 5. Soils from small arms ranges 
626 showed the highest Pb RBA value than that from other sources, which ranged from 
627 77.3% to 191%, with a median of 108.8% (Bannon et al., 2009). The mean Pb RBA 
628 value for soils from mining, smelter, dust, incinerator sites, residential and 
629 gasworks ranged from 33.8% to 44.5%. The median Pb RBA values for soils from 
630 mining, smelter and house dusts are 38%, 42% and 49.4%, respectively. Both the 
631 median and mean Pb RBA values of soils from mining and smelter sites are far 
632 below the IEUBK default value of 60%. While the values for farming sites are very 




635 3.2 Influence of soil properties on Pb bioavailability
636 Different Pb minerals are present in natural weathered soils and anthropogenic 
637 contaminated soils (e.g. smelter slags and other waste materials). Human activities 
638 may alter BA by changing the original Pb mineral phases in soils. For example, 
639 although Pb sulfide (PbS) occurs at mining, milling, smelting and ore-handing sites, 
640 it can be encapsulated with other minerals to reduce its BA (Ruby et al., 1999).
641
642 The BA of Pb in soil is influenced by the physical and chemical properties of 
643 various phases of Pb. Lead mineral phases, particle size, chemical reactions 
644 including precipitation, adsorption, and degradation in the weathering process are 
645 all believed to influence Pb BA (FaciesRuby et al., 1999; R.Naidu, 2003). As shown 
646 in Figure 6, for the same form of Pb mineral phase, its RBA increases while the 
647 particle size decreases. Lead RBA will be limited once Pb minerals are covered by 
648 quartz and slag. The RBA of Pb mineral phase followed a sequence that Pb(OH)- = 
649 PbCl-= PbBrCl > PbO = Pb3O4 = PbCO3 > Pb phosphate > PbS = Pb5(PO)4Cl = Pbo 






654 Figure 6 Lead mineral phases contribute to its bioavailability (FaciesRuby et al., 
655 1999)
656
657 Moreover, the U.S. Environmental Protection Agency (2007a) reported a group-
658 specific RBA values for various Pb minerals using swine and statistical analysis on 
659 19 mining soils. As shown in Table 9, Pb RBA of various mineral morphologies 
660 are grouped into three categories, under 25%, 25% to 75%, and above 75%. It’s 
661 worth noting that the group-specific results involve inherent uncertainties as they 
662 are only estimated using limited data sets and limited sources of soils, and many 
663 factors which can influence Pb RBA are not included (U.S. Environmental 
664 Protection Agency, 2007a). The US EPA also states that this is a semi-quantitative 
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665 rank-order classification of phase-specific RBA values (U.S. Environmental 
666 Protection Agency, 2007a). 
667
668 Table 9 A group-specific value of Pb relative bioavailability for various Pb mineral 
669 morphologies (U.S. Environmental Protection Agency, 2007a) 
Low Bioavailability (RBA 
<0.25) 
Medium Bioavailability 
(RBA = 0.25-0.75) 
High Bioavailability 
(RBA >0.75) 
Fe(M) Sulfate Anglesite 
Galena Fe(M) Oxide 
Pb(M) Oxide 
Lead Oxide Lead Phosphate Cerussite Mn(M) Oxide 
670 (M) = Metal; RBA: relative bioavailability.
671
672 Three main reactions which influence Pb RBA in soils include specific adsorption 
673 to various solid phases, precipitation of sparingly soluble or highly stable 
674 compounds, and formation of relatively stable complexes or chelates via interacting 
675 with soil organic matter (Bradl, 2004). It has been reported that soil properties like 
676 clay content, pH, OM, and CEC are related to Pb BAc (Buchter et al., 1989; He and 
677 Singh, 1993; Hornburg and Brümmer, 1993; Rieuwerts et al., 2006; Poggio et al., 
678 2009; Roussel et al., 2010). For example, OM has an immobilisation effect on Pb 
679 in soils via specific adsorption reactions (Pinheiro et al., 1999). The high CEC and 
680 OM values enhance its metal retention ability by surface complexation, ion 
681 exchange and surface precipitation (Kalbitz and Wennrich, 1998). Also it is 
682 reported that clay can effectively remove heavy metals by specific adsorption and 




685 Efforts have been made to link soil properties and Pb RBA/BAc. For example, 
686 Wijayawardena et al. (2015) investigated Pb RBA values of 11 Pb acetate spiked 
687 soils (1 year aging, from Queensland and South Australia, Australia) by the swine 
688 model. A strong correlation was found between soil properties (pH, clay, and CEC) 
689 and Pb RBA, being RBA = 131.5 – 12.9 pH - 0.5 CEC + 0.9 clay, n = 11, r2 = 0.88, 
690 p < 0.01. Jin et al. (2015) reported that Pb BAc (PBET model) is related to soil 
691 properties using spiked soils, a correlation being BAc (G-phase) = 106.8 + 
692 0.627[Pb] + 19.1[Fe] + 11.3[OM], and BAc (I-phase) = 2.852 + 0.078[Pb], where 
693 OM is organic matter; However, no relationship has been established between Pb 
694 RBA value and soil properties from field contaminated soils. Moreover, Caboche 
695 et al. (2010) and Morman et al. (2009) indicated that soil edaphic properties failed 
696 to model Pb BAc as these properties could not be extrapolated from one site to 
697 another. Hagens et al. (2009) measured Pb BAc using the RIVM model, as well as 
698 soil properties of 90 Dutch soils, including pH, OM, clay, calcium carbonate, total 
699 sulphur, and reactive iron. No relationships between Pb BAc and soil properties 
700 were found, possibly because the soils appear to have uniform soil characteristics 
701 (Hagens et al., 2009). 
702
703 Although limited relationships were reported between Pb RBA/BAc and soil 
704 properties, it was reported that Pb RBA/BAc of historically contaminated soils is 
705 influenced by soil properties and Pb speciation (Oomen et al., 2006). This study 
706 implied that Pb RBA in soils is site-specific, and it is possible to predict Pb RBA in 
707 specific soils and/or Pb types using soil properties (Hagens et al., 2009). All the 
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708 data was clustered by source of soils based on end use, such as mining, smelter, 
709 small arms ranges, gas works, shooting ranges, farming, pottery and some other 
710 industry sites. Considering the effect of soil type on Pb RBA, and the availability 
711 of data number to model, the data of mining soils was used to investigate the 
712 relationship between soil properties and Pb RBA. Soil properties of mining soils, 
713 including pH, clay, CEC, total organic carbon (TOC) and OM, were used to 
714 correlate with Pb RBA by linear regression. 
715  
716 The linear correlation between soil properties and the soils Pb RBA/BAc of mining 
717 soils from all literature data is shown in Figure 7. No significant relationship was 
718 found between the single soil properties and Pb RBA (left set in Figure 7); however, 
719 results showed that soil properties can influence Pb RBA.  Lead RBA decreases 
720 when clay content and CEC increase, this indicates that clay content and CEC may 
721 have a negative effect on Pb RBA. While for TOC and OM, a relatively weak 
722 positive trend was found for Pb RBA. For pH, most soils are neutral or even 
723 alkaline, the Pb RBA values showed a larger range compared to that for acidic soils. 
724 The literature data of Pb BAc was also collected and analysed for investigation of 
725 the relationship between soil properties and Pb RBA in addition to Pb BAc data 
726 (right set in Figure 7). Similar results were found despite the increasing amount of 
727 data. It is worth noting that the above findings are based on limited literature data, 
728 additional investigation and information will be useful to further investigate 
729 possible relationship between soil properties and Pb RBA/BAc. A key requirement 
730 of this investigation is the approach and methods used for the study unlike 
ACCEPTED MANUSCRIPT
49
731 information derived from the literature where methods adopted by researchers vary 
732 considerably.  This could be one reason for the weak relationship or no relationship 




735 Figure 7 Effect of soil properties on Pb bioavailability of mining soils
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736 3.3 Influence of metal content on Pb bioavailability
737 Published data was collected in our study to investigate the relationship between Pb 
738 concentration and BA. The distribution of Pb concentration for all mining soil 
739 samples is shown in Figure 8. Most of the samples are within the range of 2500 to 
740 12500 mg/kg (Figure 8a). More than 50% of the samples have a Pb concentration 
741 below 10000 mg/kg (Figure 8b). 
742
743
744 Figure 8 Distribution of Pb concentration for mining samples
745 References: (Freeman et al., 1992; Ruby et al., 1996; Casteel et al., 1997; Hettiarachchi et al., 2003; 
746 Schroder et al., 2004; Drexler and Brattin, 2007; Juhasz et al., 2009; Smith et al., 2011a; Denys et 
747 al., 2012; Li et al., 2015; Li et al., 2016)
748
749 Research efforts have been made to correlate total Pb concentration and Pb 
750 RBA/BAc. Roussel et al. (2010) found significant positive correlations between Pb 
751 BAc (UBM model) and total Pb concentration in 27 urban contaminated soils; 
752 However, Morman et al. (2009) reported that no correlations were found between 
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753 total metal content (Pb, As, Cd, Ni, Cr) and their BAc (RBALP model) in 20 soils 
754 from various sources. Hagens et al. (2009) also stated that there was no relationship 
755 between total Pb concentration and Pb BAc measured by RIVM model on 90 Dutch 
756 soils. Moreover, Walraven et al. (2015) reported that Pb BAc does not necessarily 
757 depend on the total Pb concentration. This was demonstrated by Casteel et al. 
758 (1997), who estimated Pb RBA on two mining soils with Pb concentration of 3870 
759 mg/kg and 14200 mg/kg, respectively.  Their results showed that the Pb RBA for 
760 these two soils was very close, 63% and 64%, respectively. 
761
762 Literature data of Pb RBA/BAc and Pb/Ca/Fe concentration was collected and a 
763 linear analysis was used to compare the influence of metal content on Pb RBA. As 
764 shown in Figure 9, no relation was found between total Pb concentration and Pb 
765 RBA/BAc. Other metals like Fe and Ca were reported to have competitive 
766 adsorption effects on Pb BAc in the intestinal phase. For example, Bi et al. (2015) 
767 found a significantly negative correlation between total Ca concentration and Pb 
768 BAc (I-phase of PBET model), which is Pb BAc (I-phase) = 22.01* [Total Ca]-1.16, 
769 r2 = 0.482. Li et al. (2014) demonstrated that Fe can co-precipitate with Pb during 
770 the I-phase indicating that a high level of Fe resulted in a lower Pb RBA. In this 
771 review, based on literature data, although no significant correlation is found 
772 between Fe concentrations to Pb RBA, a weak negative influence can be observed 
773 indicating Fe may have a competitive adsorption effect on Pb BAc in mining soils. 










780 3.4 Future perspectives
781 Despite over three decades of research on bioaccessibility and bioavailability, it is 
782 still a challenge to estimate Pb RBA due to varying soil properties and many 
783 modelling uncertainties. More research efforts is expected to minimize 
784 uncertainties in measuring Pb RBA. Further research activities could include:
785 1) To address inter-species variability between different animal models, including 
786 swine, rats, and mice, to address uncertainties of measured Pb RBA.
787 2) Considering the advantage and benefits of using in vitro models to estimate Pb 
788 RBA/BAc, it is recommended that parameter uncertainties of commonly used 
789 in vitro models are investigated and addressed. 
790 3) It is recommended that the best in vitro model to measure Pb BAc and then 
791 indicate Pb RBA is identified, and then further validated
792 4) More studies are required to research the influence of soil properties on Pb 
793 RBA/BAc, and to quantify the influence of soil properties, such as clay, CEC, 
794 OM, and TOC, to Pb RBA/BAc.
795 5) It is necessary to address the influence of competitive adsorption of metals onto 
796 soil components on Pb RBA/BAc.
797 6) To further investigate the adsorbtion/retention mechanism of Pb in soils, to offer 
798 fundamental information for the remediation of Pb contaminated soils. 
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799 4 Conclusion 
800 In this review, we summarised the existing knowledge on the measurement of Pb 
801 RBA and BAc including their key influencing parameters, IVIVC correlations, the 
802 influence of soil type and properties on Pb BA, and existing uncertainties. Among 
803 the in vitro methods, we recommended the use of RBALP and UBM models to 
804 estimate Pb BAc on mining soils/dust as they are well validated using  swine model, 
805 pH value was monitored in G-phase, and using  end-over-end rotation for mixing,. 
806 Further studies can be devised for validating the correlation between in vivo and in 
807 vitro models by addressing uncertainties from various soil properties, inter-species 
808 differences of animal models, as well as difference in vitro models.
809
810 The influence of soils including soil type, soil properties and Pb concentration on 
811 Pb RBA/BAc are also discussed in this review. It is expected that significant 
812 correlations would be found between soil properties and Pb RBA/Bac for soils from 
813 the same type; However, limited information is available for using soil properties 
814 of field Pb contaminated soils to predict Pb RBA. The influence of soil properties 
815 on Pb RBA/BAc were analysed using existing literature information in this review, 
816 which showed a negative influence of clay and CEC content on Pb RBA/BAc. 
817 Although no significant correlation was found between metals content and Pb RBA, 
818 it is reported that metals content can influence Pb RBA. Fe concentration in mining 
819 soils is found to have a weak negative influence on Pb RBA indicating that metals 
820 may have a competitive adsorption effect on Pb in mining soils.  Further 
821 investigation on the effect of soil on Pb RBA/BAc will provide help in addressing 
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822 the existing uncertainties in their measurement and provide indications on 
823 development of remediation for Pb contaminated sites. The information provided 
824 is critical and fundamental for future development of measurements for Pb 
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Highlights
1) Key parameters influencing in vitro measurements of Pb bioaccessibility in soils and 
uncertainties are summarized. 
2) Lead bioavailability varied with different soil type, soil properties and metal 
concentrations, indicating that those factors influence lead bioavailability. 
3) Differences in in vitro methods and Pb source limit statistical analysis of the soil 
factors influencing Pb bioavailability. 
